Organon & Co. top brass misrepresented its financial condition and strategy before the company said it slashed quarterly dividends about 70%, prompting a record stock selloff, a shareholder lawsuit ...

Aug 8 (Reuters) - Organon & Co (OGN.N), opens new tab reported better-than-expected second-quarter results on Tuesday, helped by strong demand for its women's heath products and biosimilar drugs ...

J.P. Morgan reevaluated its coverage of the North American specialty pharma space on Friday, downgrading the generic drugmaker Organon (NYSE ... towards complex products and biosimilars and ...

"Our work with Organon to align its pharmaceutical development with Industry 4.0 principles is crucial to supporting women's health in an efficient, expedient and compliant approach," said Surya ...

comprised of the pharma giant’s women’s health business and off-patent drugs. The Organon dermatology portfolio currently has two products: Diproson, a topical corticosteroid for skin ...

Lilly will maintain marketing authorizations for its drugs and continue to manufacture the products. In exchange for the rights, Organon is handing over an upfront payment of $50 million.